Matches in SemOpenAlex for { <https://semopenalex.org/work/W2465400545> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2465400545 abstract "Purpose:To understand the clinical impact of key uncertainties in proton therapy potentially affecting the analysis of clinical trials, namely the assumption of using a constant relative biological effectiveness (RBE) of 1.1 compared to variable RBE for proton therapy and the use of analytical dose calculation (ADC) methods.Methods:Proton dose distributions were compared for analytical and Monte Carlo (TOPAS) dose calculations. In addition, differences between using a constant RBE of 1.1 (RBE-constant) were compared with four different RBE models (to assess model variations). 10 patients were selected from an ongoing clinical trial on IMRT versus scanned protons for sarcoma. Comparisons were performed using dosimetric indices based on dose-volume histogram analyses and γ-index analyses.Results:For three of the RBE-models the mean dose, D95, D50 and D02 (dose values covering 95%, 50% and 2% of the target volume, respectively) were up to 5% lower than for RBE-constant. The dosimetric indices for one of the RBE-models were around 9% lower than for the RBE-constant model. The differences for V90 (the percentage of the target volume covered by 90% of the prescription dose) were up to 40% for three RBE-models, whereas for one the difference was around 95%. All ADC dosimetric indices were up to 5% larger than for RBE-constant. The γ-index passing rate for the target volume with a 3%/3mm criterion was above 97% for all models except for one, which was below 24%.Conclusion:Interpretation of clinical trials on sarcoma may depend on dose calculation uncertainties (as assessed by Monte Carlo). In addition, the biological dose distribution depends notably on which RBE model is utilized. The current practice of using a constant RBE of 1.1 may overestimate the target dose by as much as 5% for biological dose calculations. Performing an RBE uncertainty analysis is recommended for trial analysis.U19 projects - U19 CA 021239. PI: Delaney" @default.
- W2465400545 created "2016-07-22" @default.
- W2465400545 creator A5023199362 @default.
- W2465400545 creator A5037938903 @default.
- W2465400545 creator A5047302721 @default.
- W2465400545 date "2016-06-01" @default.
- W2465400545 modified "2023-09-27" @default.
- W2465400545 title "WE-AB-207B-06: Dose and Biological Uncertainties in Sarcoma" @default.
- W2465400545 doi "https://doi.org/10.1118/1.4957787" @default.
- W2465400545 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28047901" @default.
- W2465400545 hasPublicationYear "2016" @default.
- W2465400545 type Work @default.
- W2465400545 sameAs 2465400545 @default.
- W2465400545 citedByCount "0" @default.
- W2465400545 crossrefType "journal-article" @default.
- W2465400545 hasAuthorship W2465400545A5023199362 @default.
- W2465400545 hasAuthorship W2465400545A5037938903 @default.
- W2465400545 hasAuthorship W2465400545A5047302721 @default.
- W2465400545 hasConcept C105795698 @default.
- W2465400545 hasConcept C111337013 @default.
- W2465400545 hasConcept C11928243 @default.
- W2465400545 hasConcept C121332964 @default.
- W2465400545 hasConcept C126838900 @default.
- W2465400545 hasConcept C142724271 @default.
- W2465400545 hasConcept C185544564 @default.
- W2465400545 hasConcept C19499675 @default.
- W2465400545 hasConcept C2778256501 @default.
- W2465400545 hasConcept C2779244869 @default.
- W2465400545 hasConcept C2989005 @default.
- W2465400545 hasConcept C33923547 @default.
- W2465400545 hasConcept C509974204 @default.
- W2465400545 hasConcept C54516573 @default.
- W2465400545 hasConcept C71924100 @default.
- W2465400545 hasConcept C75088862 @default.
- W2465400545 hasConceptScore W2465400545C105795698 @default.
- W2465400545 hasConceptScore W2465400545C111337013 @default.
- W2465400545 hasConceptScore W2465400545C11928243 @default.
- W2465400545 hasConceptScore W2465400545C121332964 @default.
- W2465400545 hasConceptScore W2465400545C126838900 @default.
- W2465400545 hasConceptScore W2465400545C142724271 @default.
- W2465400545 hasConceptScore W2465400545C185544564 @default.
- W2465400545 hasConceptScore W2465400545C19499675 @default.
- W2465400545 hasConceptScore W2465400545C2778256501 @default.
- W2465400545 hasConceptScore W2465400545C2779244869 @default.
- W2465400545 hasConceptScore W2465400545C2989005 @default.
- W2465400545 hasConceptScore W2465400545C33923547 @default.
- W2465400545 hasConceptScore W2465400545C509974204 @default.
- W2465400545 hasConceptScore W2465400545C54516573 @default.
- W2465400545 hasConceptScore W2465400545C71924100 @default.
- W2465400545 hasConceptScore W2465400545C75088862 @default.
- W2465400545 hasLocation W24654005451 @default.
- W2465400545 hasOpenAccess W2465400545 @default.
- W2465400545 hasPrimaryLocation W24654005451 @default.
- W2465400545 hasRelatedWork W1869977777 @default.
- W2465400545 hasRelatedWork W1965728877 @default.
- W2465400545 hasRelatedWork W1979322350 @default.
- W2465400545 hasRelatedWork W1996025058 @default.
- W2465400545 hasRelatedWork W2078681069 @default.
- W2465400545 hasRelatedWork W2272905115 @default.
- W2465400545 hasRelatedWork W2406988819 @default.
- W2465400545 hasRelatedWork W2473719446 @default.
- W2465400545 hasRelatedWork W2473831706 @default.
- W2465400545 hasRelatedWork W2579523213 @default.
- W2465400545 hasRelatedWork W2904181709 @default.
- W2465400545 hasRelatedWork W2904195639 @default.
- W2465400545 hasRelatedWork W2964359941 @default.
- W2465400545 hasRelatedWork W2968519443 @default.
- W2465400545 hasRelatedWork W2996362046 @default.
- W2465400545 hasRelatedWork W3009433860 @default.
- W2465400545 hasRelatedWork W3081945365 @default.
- W2465400545 hasRelatedWork W3082294570 @default.
- W2465400545 hasRelatedWork W3213085574 @default.
- W2465400545 hasRelatedWork W38988356 @default.
- W2465400545 isParatext "false" @default.
- W2465400545 isRetracted "false" @default.
- W2465400545 magId "2465400545" @default.
- W2465400545 workType "article" @default.